July 2026
M	T	W	T	F	S	S
	1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

Chokri Ben Lamine: Clinical Dosing and Special Populations Guide for Apixaban

AI Generated

Apr 12, 2026, 12:56

Chokri Ben Lamine: Clinical Dosing and Special Populations Guide for Apixaban

Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:

“Apixaban Pearls (Indications, Dosing plus, and Special Populations)

Mechanism

Leads to Direct Factor Xa inhibitor leads to decrease thrombin generation

Indications

VTE treatment (DVT/PE)
Extended VTE prophylaxis
Stroke prevention in AF (NVAF)
Post-op prophylaxis (hip/knee)

Dosing (Adults)

Acute VTE

10 mg twice daily for 7 days
Then 5 mg twice daily

Extended VTE

2.5 mg twice daily after at least 6 months of treatment

AF stroke prevention

5 mg twice daily

Dose reduction AF

2.5 mg twice daily if ≥2 of the following are present:

Age ≥80 years
Body weight ≤60 kg
Serum creatinine ≥133 µmol/L (≈1.5 mg/dL)

Post-operative prophylaxis

Hip replacement: 2.5 mg twice daily for 35 days
Knee replacement: 2.5 mg twice daily for 12 days

Special Populations

Renal impairment

Creatinine clearance ≥30 mL/min: standard dosing
Creatinine clearance 15–29 mL/min: use with caution (dose reduction in atrial fibrillation)
Creatinine clearance <15 mL/min or dialysis: limited evidence; avoid use (prefer warfarin)

Hepatic disease

Mild (Child–Pugh A): use without dose adjustment
Moderate (Child–Pugh B): use with caution
Severe (Child–Pugh C): not recommended / contraindicated

Cancer-associated VTE

Preferred option: DOAC in many patients (vs LMWH, depending on bleeding risk and cancer type)
Avoid: if active gastrointestinal or genitourinary lesions due to increased bleeding risk

Obesity

BMI >40 kg/m² or weight >120 kg: use with caution
Consider drug level monitoring (anti–Xa activity) or alternative anticoagulation (LMWH or warfarin)

Elderly

Increased bleeding risk
Assess carefully for dose reduction criteria and comorbidities

Pregnancy

Not recommended
Use low-molecular-weight heparin (LMWH)

Breastfeeding

Not recommended (insufficient safety data)

Antiphospholipid syndrome (APS)

Not recommended, particularly in triple-positive APS
Prefer warfarin

Drug interactions

Strong CYP3A4/P-gp inhibitors (e.g., azoles, clarithromycin): increased bleeding risk
Strong inducers (e.g., rifampin, carbamazepine): reduced efficacy

Bleeding management